Amylyx Seeks Approval in Canada of Lead Candidate AMX0035

Amylyx Seeks Approval in Canada of Lead Candidate AMX0035

296706

Amylyx Seeks Approval in Canada of Lead Candidate AMX0035

Amylyx Pharmaceuticals is seeking approval, in Canada, of its lead candidate AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). This regulatory submission “represents a significant milestone in our efforts to develop a new treatment option for people living with ALS who have no time to wait,” Joshua Cohen, co-founder, co-CEO, and chairman of Amylyx, said in a press release. Chris Aiello, Amylyx’s head of Canada and general manager, said the company “is committed to bringing AMX0035 through the…

You must be logged in to read/download the full post.